Literature DB >> 18426370

Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.

Carmen de Mendoza1, Inmaculada Jiménez-Nacher, Carolina Garrido, Pablo Barreiro, Eva Poveda, Angélica Corral, Natalia Zahonero, Juan González-Lahoz, Vincent Soriano.   

Abstract

Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of tenofovir use. A reduction in the rate of coadministration of didanosine (from 41.6% of patients in 2004 to 0.8% of patients in 2006; P < .001) largely explained this observation.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18426370     DOI： 10.1086/588045

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  6 in total

1.  International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.

Authors:  Philip M Grant; Jonathan Taylor; Andrew B Nevins; Vincent Calvez; Anne-Geneviève Marcelin; Marc Wirden; Andrew R Zolopa
Journal:  Antimicrob Agents Chemother       Date:  2010-02-01       Impact factor: 5.191

2.  Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir.

Authors:  K Theys; J Snoeck; J Vercauteren; A B Abecasis; A-M Vandamme; R J Camacho
Journal:  J Antimicrob Chemother       Date:  2012-09-30       Impact factor: 5.790

3.  In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine.

Authors:  Susan M Schader; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Daniela Moisi; Susan P Colby-Germinario; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

4.  The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.

Authors:  Bluma G Brenner; Dimitrios Coutsinos
Journal:  HIV Ther       Date:  2009-11-01

5.  Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.

Authors:  Gilberto Betancor; César Garriga; Maria C Puertas; María Nevot; Lourdes Anta; José L Blanco; M Jesús Pérez-Elías; Carmen de Mendoza; Miguel A Martínez; Javier Martinez-Picado; Luis Menéndez-Arias; José Antonio Iribarren; Estrella Caballero; Esteban Ribera; Josep Maria Llibre; Bonaventura Clotet; Angels Jaén; David Dalmau; José María Gatel; Joaquín Peraire; Francesc Vidal; Carmen Vidal; Melchor Riera; Juan Córdoba; José López Aldeguer; María José Galindo; Félix Gutiérrez; Marta Álvarez; Federico García; Pilar Pérez-Romero; Pompeyo Viciana; Manuel Leal; José Carlos Palomares; Juan Antonio Pineda; Isabel Viciana; Jesús Santos; Patricia Rodríguez; Juan Luis Gómez Sirvent; Carolina Gutiérrez; Santiago Moreno; Mayte Pérez-Olmeda; José Alcamí; Carmen Rodríguez; Jorge del Romero; Angelina Cañizares; José Pedreira; Celia Miralles; Antonio Ocampo; Luis Morano; Antonio Aguilera; Carolina Garrido; Gustavo Manuzza; Eva Poveda; Vicente Soriano
Journal:  Retrovirology       Date:  2012-08-13       Impact factor: 4.602

6.  An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs.

Authors:  Erasmus Smit; Ellen White; Duncan Clark; Duncan Churchill; Hongyi Zhang; Simon Collins; Deenan Pillay; Caroline Sabin; Mark Nelson; Alan Winston; Sophie Jose; Anna Tostevin; David T Dunn
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.